Press Release: Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC

MORRISTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other...

We’ve Been Busy, and the Press Has Noticed!

The past few months have been an exciting time for all of us at New Day Diagnostics. Since launching ColoHealth™, our blood-based colorectal cancer screening test, we've been honored to see our story featured in over 200 independent news articles across the country. ...